Celgene investors’ CVR payment looks rocky, as FDA rejects i...

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft

Saunders steps aside as AbbVie closes in on Allergan merger

Menarini bags blood cancer drug with $677M Stemline acquisit...

Antitrust delay scuppers Novartis’ $1bn generics sale to Aur...

Lilly swoops on Dermira to claim Dupixent rival

Sumitomo, Roivant close $3 billion deal, forming Sumitovant